[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659877":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":17,"armGroups":23,"interventions":29,"overallOfficials":17,"centralContacts":35,"locations":17,"responsibleParty":41,"collaborators":17,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":17,"enrollmentInfo":53,"targetDuration":17,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":17,"overallStatus":62,"whyStopped":17,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":17},{"fullName":5,"class":6},"Khyber Girls Medical College","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":17},[9,13],{"measure":10,"description":11,"timeFrame":12},"Change in BCVA(logMAR) from baseline to 6 months","whether there is improvement in Visual acuity after SCTA","from enrollment of participants to final outcome measurement at 6 month",{"measure":14,"description":15,"timeFrame":16},"change in Visual acuity","measured in logMAR","from baseline to 6 months",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":6,"observationalModel":17,"timePerspective":17,"maskingInfo":21},"NA","SINGLE_GROUP",{"masking":22,"maskingDescription":17,"whoMasked":17},"NONE",[24],{"label":25,"type":26,"description":25,"interventionNames":27},"SCTA monotherapy","EXPERIMENTAL",[28],"Drug: Suprachoroidal triamcinolone acetonide injection",[30],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":17},"DRUG","Suprachoroidal triamcinolone acetonide injection","4mg\u002F0.1 ml, given once at baseline",[25],[36],{"name":37,"role":38,"phone":39,"phoneExt":17,"email":40},"Saima Farooq, MBBS, FCPS","CONTACT","+923339977188","saaima_farooq@yahoo.com",{"type":42,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100659877","phase-2-suprachoroidal-triamcinolone-acetonide-monotherapy-in-treatment-naive-center-involving-diabetic-macular-edema-100659877",false,"NCT07870226","Suprachoroidal Triamcinolone Acetonide Monotherapy in Treatment-naive Center Involving Diabetic Macular Edema","Outcomes of Suprachoroidal Triamcinolone Acetonide Monotherapy in Treatment-Naïve Center-Involving Diabetic Macular Edema","SCTA CI-DME","Inclusion Criteria: adults aged ≥18 years with type 1 or type 2 diabetes mellitus and center-involving diabetic macular edema (DME), with best-corrected visual acuity (BCVA) between 6\u002F12 and 6\u002F60 (Snellen), central subfield thickness (CST) \\>320 µm on OCT macula (Spectralis SD-OCT), and diabetic retinopathy severity no worse than severe non-proliferative diabetic retinopathy (NPDR). The study eye must be treatment-naive, with no prior anti-VEGF therapy, intravitreal or periocular steroid, or focal\u002Fgrid laser for DME.\n\n\\-\n\nExclusion Criteria: any other ocular disease compromising visual acuity (e.g., retinal vein occlusion, age-related macular degeneration, retinal detachment, uveitis, or vitreomacular traction\u002Fepiretinal membrane contributing to edema); a history of glaucoma, current use of IOP-lowering medication, or baseline IOP \\>21 mmHg; any intraocular surgery within the preceding 3 months; panretinal photocoagulation for severe NPDR or proliferative DR within the preceding 3 months; media opacity precluding reliable OCT imaging or fundus examination; a history of significant steroid-response IOP rise; or pregnancy\u002Fbreastfeeding.\n\n\\-","ALL","18 Years",{"count":54,"type":55},25,"ESTIMATED","INTERVENTIONAL",[58],"PHASE2","The goal of this clinical trial is to evaluate whether a single injection of suprachoroidal triamcinolone acetonide (SCTA) improves visual outcomes in patients with treatment-naive diabetic macular edema involving the center of the macula. The study will also evaluate the safety of SCTA by monitoring for possible side effects, including an increase in intraocular pressure and cataract progression.\n\nPatients will be evaluated at the start of the study (baseline) and will receive one injection of SCTA. They will then be followed at 1, 3, and 6 months. At each follow-up visit, visual acuity, central macular thickness, intraocular pressure, and cataract status will be assessed to evaluate the effectiveness and safety of the treatment.",[61],"Diabetic Macular Edema","NOT_YET_RECRUITING","2026-10-06",{"date":65,"type":66},"2026-10-13","ACTUAL",{"date":68,"type":55},"2026-09-21",{"date":70,"type":55},"2027-06",{"name":5,"class":6}]